26.10.2015 Views

Global Pneumonia Clinical Trials Review Market Research & Analysis Report 2015 Radiant Insights, Inc

Summary Radiant Insights's clinical trial report, "Pneumonia Global Clinical Trials Review, H1, 2015" provides an overview of Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Radiant Insights Clinical Trial Reports are generated using Radiant Insights proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Browse Full Report With TOC @ http://www.radiantinsights.com/research/pneumonia-global-clinical-trials-review-h1-2015 The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Reasons to buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level

Summary

Radiant Insights's clinical trial report, "Pneumonia Global Clinical Trials Review, H1, 2015" provides an overview of Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Radiant Insights Clinical Trial Reports are generated using Radiant Insights proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Browse Full Report With TOC @ http://www.radiantinsights.com/research/pneumonia-global-clinical-trials-review-h1-2015

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Global</strong> <strong>Pneumonia</strong> <strong>Clinical</strong> <strong>Trials</strong> <strong>Review</strong> <strong>Market</strong> <strong>Research</strong> &<br />

<strong>Analysis</strong> <strong>Report</strong> <strong>2015</strong> <strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />

Summary<br />

<strong>Radiant</strong> <strong>Insights</strong>'s clinical trial report, "<strong>Pneumonia</strong> <strong>Global</strong> <strong>Clinical</strong> <strong>Trials</strong> <strong>Review</strong>, H1, <strong>2015</strong>" provides an<br />

overview of <strong>Pneumonia</strong> clinical trials scenario. This report provides top line data relating to the clinical<br />

trials on <strong>Pneumonia</strong>. <strong>Report</strong> includes an overview of trial numbers and their average enrollment in top<br />

countries conducted across the globe. The report offers coverage of disease clinical trials by region,<br />

country (G7 & E7), phase, trial status, end points status and sponsor type. <strong>Report</strong> also provides prominent<br />

drugs for in-progress trials (based on number of ongoing trials). <strong>Radiant</strong> <strong>Insights</strong> <strong>Clinical</strong> Trial <strong>Report</strong>s<br />

are generated using <strong>Radiant</strong> <strong>Insights</strong> proprietary database - Pharma eTrack <strong>Clinical</strong> trials database.<br />

<strong>Clinical</strong> trials are collated from 80+ different clinical trial registries, conferences, journals, news etc<br />

across the globe. <strong>Clinical</strong> trials database undergoes periodic update by dynamic process.<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

The report enhances the decision making capabilities and helps to create an effective counter strategies to<br />

gain competitive advantage.<br />

Scope<br />

- The report provides a snapshot of the global clinical trials landscape<br />

- <strong>Report</strong> provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status,<br />

Trial Phase, Sponsor Type and End point status<br />

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining<br />

to the company<br />

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason<br />

for unaccomplishment<br />

- The <strong>Report</strong> provides enrollment trends for the past five years<br />

- <strong>Report</strong> provides latest news for the past three months<br />

Reasons to buy<br />

- Assists in formulating key business strategies with regards to investment<br />

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost


- Provides top level analysis of <strong>Global</strong> <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong> which helps in identifying key business<br />

opportunities<br />

- Supports understanding of trials count and enrollment trends by country in global therapeutics market<br />

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed<br />

and uncompleted (terminated, suspended or withdrawn) trials<br />

- Facilitates clinical trial assessment of the indication on a global, regional and country level<br />

Table of Contents<br />

Table of Contents 2<br />

List of Tables 4<br />

List of Figures 5<br />

Introduction 6<br />

<strong>Pneumonia</strong> 6<br />

<strong>Report</strong> Guidance 6<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

<strong>Clinical</strong> <strong>Trials</strong> by Region 7<br />

<strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Country 8<br />

Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Asia-Pacific 10<br />

Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Europe 11<br />

Top Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in North America 12<br />

Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Middle East and Africa 13<br />

Top Five Countries Contributing to <strong>Clinical</strong> <strong>Trials</strong> in Central and South America 14<br />

<strong>Clinical</strong> <strong>Trials</strong> by G7 Countries: Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong> 15<br />

<strong>Clinical</strong> <strong>Trials</strong> by Phase in G7 Countries 16<br />

<strong>Clinical</strong> <strong>Trials</strong> in G7 Countries by Trial Status 17<br />

<strong>Clinical</strong> <strong>Trials</strong> by E7 Countries: Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong> 18


<strong>Clinical</strong> <strong>Trials</strong> by Phase in E7 Countries 19<br />

<strong>Clinical</strong> <strong>Trials</strong> in E7 Countries by Trial Status 20<br />

<strong>Clinical</strong> <strong>Trials</strong> by Phase 21<br />

In Progress <strong>Trials</strong> by Phase 22<br />

<strong>Clinical</strong> <strong>Trials</strong> by Trial Status 23<br />

<strong>Clinical</strong> <strong>Trials</strong> by End Point Status 24<br />

Unaccomplished <strong>Trials</strong> of <strong>Pneumonia</strong> 25<br />

Subjects Recruited Over a Period of Time 31<br />

<strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type 32<br />

Prominent Sponsors 33<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

Top Companies Participating in <strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> 34<br />

Prominent Drugs 35<br />

Latest <strong>Clinical</strong> <strong>Trials</strong> News on <strong>Pneumonia</strong> 36<br />

Mar 26, <strong>2015</strong>: Aridis Pharmaceuticals Commences Phase 1 <strong>Clinical</strong> Study of Aerucin Monoclonal<br />

Antibody for Acute <strong>Pneumonia</strong> 36<br />

<strong>Clinical</strong> Trial Profiles 37<br />

<strong>Clinical</strong> Trial Overview of Top Companies 37<br />

Pfizer <strong>Inc</strong>. 37<br />

<strong>Clinical</strong> Trial Overview of Pfizer <strong>Inc</strong>. 37<br />

GlaxoSmithKline Plc 42<br />

<strong>Clinical</strong> Trial Overview of GlaxoSmithKline Plc 42<br />

AstraZeneca Plc 45<br />

<strong>Clinical</strong> Trial Overview of AstraZeneca Plc 45<br />

Sanofi 47<br />

<strong>Clinical</strong> Trial Overview of Sanofi 47


Merck & Co., <strong>Inc</strong>. 49<br />

<strong>Clinical</strong> Trial Overview of Merck & Co., <strong>Inc</strong>. 49<br />

Actavis plc 51<br />

<strong>Clinical</strong> Trial Overview of Actavis plc 51<br />

Johnson & Johnson 53<br />

<strong>Clinical</strong> Trial Overview of Johnson & Johnson 53<br />

Bayer AG 55<br />

<strong>Clinical</strong> Trial Overview of Bayer AG 55<br />

Forest Laboratories, <strong>Inc</strong>. 57<br />

<strong>Clinical</strong> Trial Overview of Forest Laboratories, <strong>Inc</strong>. 57<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

Cempra, <strong>Inc</strong>. 58<br />

<strong>Clinical</strong> Trial Overview of Cempra, <strong>Inc</strong>. 58<br />

<strong>Clinical</strong> Trial Overview of Top Institutes / Government 59<br />

The National Institute of Allergy and Infectious Diseases 59<br />

<strong>Clinical</strong> Trial Overview of The National Institute of Allergy and Infectious Diseases 59<br />

Medical University of Vienna 61<br />

<strong>Clinical</strong> Trial Overview of Medical University of Vienna 61<br />

Nagasaki Evaluation Organization for <strong>Clinical</strong> Interventions 62<br />

<strong>Clinical</strong> Trial Overview of Nagasaki Evaluation Organization for <strong>Clinical</strong> Interventions 62<br />

Tohoku University 63<br />

<strong>Clinical</strong> Trial Overview of Tohoku University 63<br />

Arak University of Medical Sciences 64<br />

<strong>Clinical</strong> Trial Overview of Arak University of Medical Sciences 64<br />

Eunice Kennedy Shriver National Institute of Child Health and Human Development 65


<strong>Clinical</strong> Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human<br />

Development 65<br />

Kermanshah University of Medical Sciences 66<br />

<strong>Clinical</strong> Trial Overview of Kermanshah University of Medical Sciences 66<br />

National Taiwan University Hospital 67<br />

<strong>Clinical</strong> Trial Overview of National Taiwan University Hospital 67<br />

Ono Municipal Hospital 68<br />

<strong>Clinical</strong> Trial Overview of Ono Municipal Hospital 68<br />

St. Antonius Hospital 69<br />

<strong>Clinical</strong> Trial Overview of St. Antonius Hospital 69<br />

Five Key <strong>Clinical</strong> Profiles 70<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

Appendix 123<br />

Abbreviations 123<br />

Definitions 123<br />

<strong>Research</strong> Methodology 124<br />

Secondary <strong>Research</strong> 124<br />

About <strong>Global</strong>Data 125<br />

Contact Us 125<br />

Disclaimer 125<br />

Source 125<br />

List of Tables<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region, <strong>2015</strong>* 7<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top Countries, <strong>2015</strong>* 8<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries, <strong>2015</strong>* 9


<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Five Countries, <strong>2015</strong>* 10<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Five Countries, <strong>2015</strong>* 11<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, North America, Top Countries, <strong>2015</strong>* 12<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Middle East and Africa, Top Five Countries, <strong>2015</strong>* 13<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Central and South America, Top Five Countries, <strong>2015</strong>* 14<br />

Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%), <strong>2015</strong>* 15<br />

<strong>Pneumonia</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />

<strong>Pneumonia</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />

Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, E7 Countries (%), <strong>2015</strong>* 18<br />

<strong>Pneumonia</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 19<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

<strong>Pneumonia</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 20<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 21<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Phase <strong>2015</strong>* 22<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 24<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, Suspended <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 25<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, Withdrawn <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 26<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, Terminated <strong>Clinical</strong> <strong>Trials</strong>, <strong>2015</strong>* 27<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target Trends, 2010-2014 31<br />

<strong>Pneumonia</strong> Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type, <strong>2015</strong>* 32<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 33<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase, <strong>2015</strong>* 34<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by Prominent Drugs, <strong>2015</strong>* 35<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Pfizer <strong>Inc</strong>., <strong>2015</strong>* 37


<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by GlaxoSmithKline Plc, <strong>2015</strong>*<br />

42<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by AstraZeneca Plc, <strong>2015</strong>* 45<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sanofi, <strong>2015</strong>* 47<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Merck & Co., <strong>Inc</strong>., <strong>2015</strong>* 49<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Actavis plc, <strong>2015</strong>* 51<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Johnson & Johnson, <strong>2015</strong>* 53<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Bayer AG, <strong>2015</strong>* 55<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Forest Laboratories, <strong>Inc</strong>.,<br />

<strong>2015</strong>* 57<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Cempra, <strong>Inc</strong>., <strong>2015</strong>* 58<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by The National Institute of<br />

Allergy and Infectious Diseases, <strong>2015</strong>* 59<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Medical University of Vienna,<br />

<strong>2015</strong>* 61<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Nagasaki Evaluation<br />

Organization for <strong>Clinical</strong> Interventions, <strong>2015</strong>* 62<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Tohoku University, <strong>2015</strong>* 63<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Arak University of Medical<br />

Sciences, <strong>2015</strong>* 64<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Eunice Kennedy Shriver<br />

National Institute of Child Health and Human Development, <strong>2015</strong>* 65<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Kermanshah University of<br />

Medical Sciences, <strong>2015</strong>* 66<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by National Taiwan University<br />

Hospital, <strong>2015</strong>* 67<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Ono Municipal Hospital,<br />

<strong>2015</strong>* 68


<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong> <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by St. Antonius Hospital, <strong>2015</strong>*<br />

69<br />

List of Figures<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Region (%), <strong>2015</strong>* 7<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> and Average Enrollment by Top Countries, <strong>2015</strong>* 8<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Top Countries, <strong>2015</strong>* 9<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Asia-Pacific, Top Five Countries (%), <strong>2015</strong>* 10<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Europe, Top Five Countries (%), <strong>2015</strong>* 11<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, North America, Top Countries (%), <strong>2015</strong>* 12<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Middle East and Africa, Top Five Countries (%), <strong>2015</strong>* 13<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, Central and South America, Top Five Countries (%), <strong>2015</strong>* 14<br />

Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, G7 Countries (%), <strong>2015</strong>* 15<br />

<strong>Pneumonia</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 16<br />

<strong>Pneumonia</strong> Therapeutics, G7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 17<br />

Proportion of <strong>Pneumonia</strong> to Infectious Disease <strong>Clinical</strong> <strong>Trials</strong>, E7 Countries (%), <strong>2015</strong>* 18<br />

<strong>Pneumonia</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Phase, <strong>2015</strong>* 19<br />

<strong>Pneumonia</strong> Therapeutics, E7 Countries, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 20<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Phase (%), <strong>2015</strong>* 21<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> In Progress by Phase, <strong>2015</strong>* 22<br />

<strong>Pneumonia</strong> Therapeutics, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Trial Status, <strong>2015</strong>* 23<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, by End Point Status, <strong>2015</strong>* 24<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Average Enrollment Target Trends, 2010-2014 31<br />

<strong>Pneumonia</strong> Therapeutics <strong>Market</strong>, <strong>Global</strong>, <strong>Clinical</strong> <strong>Trials</strong> by Sponsor Type (%), <strong>2015</strong>* 32<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Key Sponsors, <strong>2015</strong>* 33


<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Top Companies by Phase, <strong>2015</strong>* 34<br />

<strong>Pneumonia</strong> Therapeutics <strong>Clinical</strong> <strong>Trials</strong>, <strong>Global</strong>, Ongoing <strong>Clinical</strong> <strong>Trials</strong> by Prominent Drugs, <strong>2015</strong>* 35<br />

<strong>Radiant</strong> <strong>Insights</strong> Methodology 124<br />

Browse Full <strong>Report</strong> With TOC @ http://www.radiantinsights.com/research/pneumonia-globalclinical-trials-review-h1-<strong>2015</strong><br />

About <strong>Radiant</strong> <strong>Insights</strong><br />

<strong>Radiant</strong> <strong>Insights</strong> is a platform for companies looking to meet their market research and business<br />

intelligence requirements. We assist and facilitate organizations and individuals procure market research<br />

reports, helping them in the decision making process. We have a comprehensive collection of reports,<br />

covering over 40 key industries and a host of micro markets. In addition to over extensive database of<br />

reports, our experienced research coordinators also offer a host of ancillary services such as, research<br />

partnerships/ tie-ups and customized research solutions.<br />

For More Information, Visit <strong>Radiant</strong> <strong>Insights</strong><br />

Contact:<br />

Michelle Thoras<br />

Corporate Sales Specialist, USA<br />

<strong>Radiant</strong> <strong>Insights</strong>, <strong>Inc</strong><br />

Phone: 1-415-349-0054<br />

Toll Free: 1-888-202-9519<br />

Email: sales@radiantinsights.com<br />

Blog URL: http://www.radiantinsightsinc.blogspot.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!